Future therapies for eosinophilic gastrointestinal disorders

Robert D. Pesek, Sandeep K. Gupta

Research output: Contribution to journalReview article

Abstract

Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selection: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.

Original languageEnglish (US)
JournalAnnals of Allergy, Asthma and Immunology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
Clinical Trials
Interleukin-13
Information Storage and Retrieval
Interleukin-5
PubMed
Integrins
Interleukin-4
Adrenal Cortex Hormones
Therapeutics
Monoclonal Antibodies
Research

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pulmonary and Respiratory Medicine

Cite this

Future therapies for eosinophilic gastrointestinal disorders. / Pesek, Robert D.; Gupta, Sandeep K.

In: Annals of Allergy, Asthma and Immunology, 01.01.2019.

Research output: Contribution to journalReview article

@article{98ba649cbc99428592afdc76334cb8ef,
title = "Future therapies for eosinophilic gastrointestinal disorders",
abstract = "Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selection: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.",
author = "Pesek, {Robert D.} and Gupta, {Sandeep K.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.anai.2019.11.018",
language = "English (US)",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",

}

TY - JOUR

T1 - Future therapies for eosinophilic gastrointestinal disorders

AU - Pesek, Robert D.

AU - Gupta, Sandeep K.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selection: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.

AB - Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selection: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85077150907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077150907&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2019.11.018

DO - 10.1016/j.anai.2019.11.018

M3 - Review article

C2 - 31778820

AN - SCOPUS:85077150907

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

ER -